GlassScriptPhysician profile
Michael M Foote
NPI 1528177193
$6,745.05
in general payments reported to CMS, 2019-2025
30 companies · $23.10 in 2025
The $23.10 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,060 · 2020: $1,037 · 2021: $1,052 · 2022: $896 · 2023: $1,762 · 2024: $914 · 2025: $23.10.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,699 · Consulting Fee: $1,000.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,699.45 |
| Consulting Fee | $1,000.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,102.16 | 2021-2023 | Alinity M, Freestyle Libre 2 |
| Glaxosmithkline, LLC. | $937.24 | 2019-2024 | Shingrix, Trelegy Ellipta, Arexvy |
| Pfizer INC. | $772.50 | 2019-2024 | |
| Novo Nordisk INC | $589.60 | 2019-2025 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $570.76 | 2019-2024 | Farxiga, Breztri, Airsupra |
| Abbvie INC. | $397.50 | 2019-2024 | |
| Lilly USA, LLC | $391.41 | 2019-2024 | Mounjaro, Jardiance, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $372.07 | 2019-2023 | Synjardy, Jardiance |
| Janssen Pharmaceuticals, INC | $315.17 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $183.25 | 2019-2022 | |
| Allergan, INC. | $182.57 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $166.46 | 2019-2021 | |
| Amgen INC. | $165.19 | 2019-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $73.15 | 2022 | |
| Sanofi-Aventis U.S. LLC | $71.49 | 2022-2023 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $68.96 | 2019-2021 | |
| Dynavax Technologies Corporation | $67.11 | 2023-2024 | Heplisav-B |
| Exact Sciences Corporation | $53.19 | 2023-2024 | Cologuard Collection Kit |
| Phathom Pharmaceuticals, INC. | $48.49 | 2024 | Voquezna |
| Collegium Pharmaceutical, INC. | $33.40 | 2021-2022 | |
| Esperion Therapeutics, INC. | $26.47 | 2020-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $25.49 | 2021-2022 | |
| Genentech USA, INC. | $23.16 | 2019 | |
| Insulet Corporation | $21.75 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $18.71 | 2023 | |
| Phadia US INC. | $16.74 | 2021 | |
| Lupin INC. | $16.32 | 2020 | |
| Biohaven Pharmaceuticals, INC. | $12.46 | 2021 | |
| Shire North American Group INC | $11.39 | 2019 | |
| Metuchen Pharmaceuticals | $10.89 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Foote listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.